Schlenk, R. F., Paschka, P., Krzykalla, J., Weber, D., Kapp-Schwoerer, S., Gaidzik, V. I., . . . Döhner, H. (2019). Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 phase III study. Journal of clinical oncology, 38(6), . https://doi.org/10.1200/JCO.19.01406
Chicago-Zitierstil (17. Ausg.)Schlenk, Richard Friedrich, et al. "Gemtuzumab Ozogamicin in NPM1-mutated Acute Myeloid Leukemia: Early Results from the Prospective Randomized AMLSG 09-09 Phase III Study." Journal of Clinical Oncology 38, no. 6 (2019). https://doi.org/10.1200/JCO.19.01406.
MLA-Zitierstil (9. Ausg.)Schlenk, Richard Friedrich, et al. "Gemtuzumab Ozogamicin in NPM1-mutated Acute Myeloid Leukemia: Early Results from the Prospective Randomized AMLSG 09-09 Phase III Study." Journal of Clinical Oncology, vol. 38, no. 6, 2019, https://doi.org/10.1200/JCO.19.01406.